GSK chief executive Emma Walmsley said the new HQ is "an important next step" for the company, which has been under pressure of late following pipeline setbacks and an investor revolt.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

MARIETTA, Pa. (WHTM) — A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster County manufacturing facility. During a press ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Also Read: GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement. Over half of all women are affected by uUTIs in their lifetime, with approximately 30% suffering from recurrent disease. New ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...